Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.

On Wednesday, Catalyst Pharmaceuticals Inc. (NASDAQ ... Teva will not market its generic version of Firdapse in the United States before February 25, 2035, unless certain limited circumstances ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - January 6 ...

Hill, Linda A., Allison J. Wigen, and Ruth Page. "Cristina Ventura: The Career of a Catalyst." Harvard Business School Multimedia/Video Case 425-708, August 2024.

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...

Catalyst Pharmaceuticals (CPRX) announced that the company and its licensor SERB S.A. have entered into a Settlement Agreement with Teva ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week.